Search for: "MERRELL v. MERRELL" Results 61 - 80 of 526
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
13 May 2020, 2:03 am by Schachtman
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 592 n.10 (1993). [3]  Id., citing Bourjaily v. [read post]
11 May 2020, 1:09 am by Schachtman
In the face of this traditional judicial lassitude, “[v]igorous cross-examination, presentation of contrary evidence, and careful instruction on the burden of proof” were all a litigant could hope to accomplish in litigation. [read post]
8 May 2020, 3:47 am by Schachtman
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [2]  Frye v. [read post]
23 Feb 2020, 9:54 am by Schachtman
Merrell Dow did not have to rule out any possibility of causation; the plaintiffs had to establish causation. [read post]
23 Jan 2020, 10:37 pm by Schachtman
The phosphodiesterases 5 inhibitor medications (PDE5i) seem to arouse the litigation propensities of the lawsuit industry. [read post]
18 Oct 2019, 10:02 am by William K. Berenson
Merrell Dow Pharms. and the Texas Supreme Court  in E.I. du Pont de Nemours v. [read post]
8 Oct 2019, 2:25 pm by Unknown
Merrell Dow Pharm., Inc., 509 U.S. 579, 589–95 (1993); see also Goebel v. [read post]
13 Sep 2019, 6:00 am by Guest Blogger
[vi]And then-Justice Rehnquist might have joined the majority in Washington v. [read post]
13 Jul 2019, 8:53 am by Schachtman
”). [3]  Bench Book at 137; see also id. at 162. [4]  Bench Book at 148. [5]  Bench Book at 160. [6]  Bench Book at 152. [7]  Bench Book at 233, quoting Daubert v. [read post]